Viking starts oral Phase 3 program for Viking Therapeutics stock

Published on 10/15/2026 at 12:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

SUNRISE-1 and SUNRISE-2 will each enroll 560 adults in the oral VK2735 trials. Viking Therapeutics stock has a USD 102.00 target.

Oral program and analyst targets

Viking announced two oral VK2735 Phase 3 studies on October 14, 2026, each targeting 560 adults.
H.C. Wainwright reiterated a USD 102.00 price target on October 14, 2026.
Viking Therapeutics stock traded at EUR 23.00 at 12:31 p.m. CEST at Lang & Schwarz on October 15, 2026.

VKTX, US92686J1060, Illustration mit AI erstellt.

Viking Therapeutics (ISIN US92686J1060) announced on October 14, 2026, that it had started the SUNRISE Phase 3 program for oral VK2735, with two studies targeting 560 adults each. The company is testing a daily tablet in obesity and obesity with type 2 diabetes, according to Viking Therapeutics.

Two studies define the next test

The SUNRISE-1 and SUNRISE-2 trials will assign participants to daily doses of 27.5 mg, 35 mg, 55 mg or placebo for 68 weeks. Their primary endpoint is the percentage change in body weight compared with placebo after 68 weeks, while secondary measures include weight-loss thresholds of 5 percent, 10 percent, 15 percent and 20 percent, as Investing.com reported on October 14, 2026.

The chronology shows how quickly the oral strategy has advanced. On October 7, 2026, Canaccord Genuity maintained a USD 114.00 target, according to Markets Insider. On October 12, 2026, Oppenheimer raised its target from USD 100.00 to USD 120.00, according to Yahoo Finance. On October 14, 2026, H.C. Wainwright reiterated a Buy rating and a USD 102.00 target, as Markets Insider reported.

What does the trial mean for valuation?

The oral program gives Viking a second development route alongside injectable VK2735. Its earlier VENTURE-Oral study produced mean weight loss of up to 12.2 percent after 13 weeks, while up to 80 percent of participants achieved at least 10 percent weight loss, compared with 5 percent for placebo, according to the October 14, 2026 release carried by Yahoo Finance. The key valuation question is whether Phase 3 can reproduce that signal with longer treatment and broader patient groups.

Viking stock stays tied to trial execution

Viking is a clinical-stage biotechnology company focused on metabolic and endocrine disorders. Its second-quarter 2026 GAAP net loss was USD 128.02 million, compared with USD 65.56 million in the year-earlier quarter, according to Markets Insider. The development timetable therefore remains central to the investment case, with the oral and injectable programs requiring separate clinical execution.